Tovorafenib - Day One Biopharmaceuticals
Alternative Names: AMG-2112819; BIIB 024 - Day One Biopharmaceuticals; BIIB-024; BSK 1369; DAY-101; MLN 2480; OJEMDA; TAK 580Latest Information Update: 02 May 2024
At a glance
- Originator Biogen Idec; Sunesis Pharmaceuticals
- Developer Day One Biopharmaceuticals; National Cancer Institute (USA); Takeda Oncology
- Class Amides; Antineoplastics; Pyridines; Pyrimidines; Small molecules; Thiazoles
- Mechanism of Action Raf kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Glioma
- Phase II Craniopharyngioma; Langerhans cell histiocytosis; Solid tumours
- Discontinued Malignant melanoma
Most Recent Events
- 29 Apr 2024 Launched for Glioma (In adolescents, In children, In infants, Second-line therapy or greater) in USA (PO) - First Global Launch
- 23 Apr 2024 Discontinued - Phase-I for Malignant melanoma (Combination therapy, Inoperable/Unresectable, Late-stage disease) in USA (PO) (Day One Biopharmaceuticals pipeline, April 2024)
- 23 Apr 2024 Discontinued - Phase-I for Malignant melanoma (Second-line therapy or greater) in United Kingdom, USA (PO) (Day One Biopharmaceuticals pipeline, April 2024)